Proglucagon-Derived Peptides as Therapeutics.

Frontiers in Endocrinology
Ryan A LaffertyPeter R Flatt

Abstract

Initially discovered as an impurity in insulin preparations, our understanding of the hyperglycaemic hormone glucagon has evolved markedly over subsequent decades. With description of the precursor proglucagon, we now appreciate that glucagon was just the first proglucagon-derived peptide (PGDP) to be characterised. Other bioactive members of the PGDP family include glucagon-like peptides -1 and -2 (GLP-1 and GLP-2), oxyntomodulin (OXM), glicentin and glicentin-related pancreatic peptide (GRPP), with these being produced via tissue-specific processing of proglucagon by the prohormone convertase (PC) enzymes, PC1/3 and PC2. PGDP peptides exert unique physiological effects that influence metabolism and energy regulation, which has witnessed several of them exploited in the form of long-acting, enzymatically resistant analogues for treatment of various pathologies. As such, intramuscular glucagon is well established in rescue of hypoglycaemia, while GLP-2 analogues are indicated in the management of short bowel syndrome. Furthermore, since approval of the first GLP-1 mimetic for the management of Type 2 diabetes mellitus (T2DM) in 2005, GLP-1 therapeutics have become a mainstay of T2DM management due to multifaceted and sustainabl...Continue Reading

References

Sep 1, 1976·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·F SundbyA J Moody
Jul 1, 1992·Diabetes Research and Clinical Practice·A M RosenfalckC Binder
May 1, 1987·The Journal of Clinical Endocrinology and Metabolism·K S Nair
Jun 1, 1988·The Tohoku Journal of Experimental Medicine·A Ohneda, M Ohneda
Oct 14, 1988·Diabetes Research and Clinical Practice·A OhnedaH Takahashi
Nov 1, 1987·Diabetologia·C OrskovP Kirkegaard
Jan 1, 1987·The Journal of Clinical Endocrinology and Metabolism·G M ReavenJ B Jaspan
Mar 1, 1987·Diabetes Research and Clinical Practice·A OhnedaY Maruyama
Mar 1, 1987·Diabetes Research and Clinical Practice·A Ohneda
Jul 1, 1972·Gut·S R Bloom
Aug 1, 1971·Canadian Journal of Biochemistry·J C Brown, J R Dryburgh
Jan 1, 1969·Canadian Journal of Physiology and Pharmacology·J C BrownV Mutt
Mar 6, 1980·Nature·G I BellH M Goodman
Apr 16, 1982·Molecular and Cellular Biochemistry·V J Hruby
May 1, 1980·The Biochemical Journal·J J Holst
May 1, 1981·Regulatory Peptides·L Thim, A J Moody
Jan 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·P K LundJ F Habener
Jan 1, 1995·Metabolism: Clinical and Experimental·A OhnedaK Sasaki
Nov 1, 1994·Molecular and Cellular Endocrinology·M SvobodaP Robberecht
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·Y RouilléD F Steiner
Feb 1, 1993·Archives of Biochemistry and Biophysics·C G UnsonR B Merrifield
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·D J DruckerP L Brubaker
Jan 1, 1997·Annual Review of Physiology·J J Holst
Jun 1, 1997·Journal of Gastroenterology·S MyojoT Bamba
Nov 14, 1998·The American Journal of Physiology·R B ScottJ B Meddings

❮ Previous
Next ❯

Software Mentioned

ENERGIZE
PIONEER

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.